Aerie Acquires Envisia Technology for $25M to Advance Retinal Program

October 6, 2017: By Jon Swedien

AerieAerie Pharmaceuticals announced Oct. 5 that it has acquired from Envisia Therapeutics the rights to use its PRINT technology in ophthalmology, along with certain other assets.

The PRINT technology is Envisia’s proprietary system for sustained-release products.

Under the terms of the agreement, Envisia will receive $25 million upfront in a combination of cash and Aerie common stock. Envisia, of Durham, North Carolina, could earn more based on certain product approval milestones, Aerie said.

Aerie, of Irvine, California, said it intends to use the technology to accelerate the advancement of its pipeline to treat conditions in the back of the eye, such as wet age-related macular degeneration and diabetic retinopathy.

Aerie’s initial focus will be in using PRINT to manufacture injectable implants containing its preclinical product candidate known as AR-13154, a potential wet AMD treatment.

This potentially could be done in conjunction with a biodegradable polymer from DSM, a Netherlands-based company that Aerie struck a collaborative agreement with in July.

In addition, Aerie acquired the intellectual property rights relating to ENV1105, Envisia’s preclinical dexamethasone steroid product candidate for the treatment of diabetic macular edema, which also uses the PRINT technology, Aerie said.

Need Deeper Analysis? Sign up for Market Scope's monthly newsletter to get in-depth coverage of the ophthalmic market, including quarterly procedure volumes based on survey data and meeting coverage from around the world.

Recent Ophthalmic News

Refocus Completes PMA Application for VisAbility as Treatment for Presbyopia

Novaliq’s NovaTears+Omega-3 Approved in Europe for Dry Eye

CooperVision Acquires Paragon Vision Sciences for $80 Million

AYOXXA Biosystems Launches Test for Biomarkers in Retinal Disease

Glaukos Announces New Patent for Glaucoma Stent Implanted in Schlemm’s Canal

Fortress Biotech Forms Tamid Bio Subsidiary; Lead Candidate is Ophthalmic Gene Therapy for MPS I

Samsung Launches App that Adjusts QLED TV Settings for Color-blind Viewers

Solar Eclipse Burns Crescent Wound in Woman’s Unprotected Retina

US Judge Refuses to Dismiss Allergan Suit against Imprimis

BioLight Sells IOPtima to Chengdu Kanghong Pharmaceutical Group for $56 Million

Regeneron Ending Eylea, Nesvacumab Combo Program

UK Retinal Drugmaker Exonate Forms Clinical Advisory Board

US FDA Approves RxSight’s Light Adjustable Lens and Light Delivery Device

EMA to Move to Amsterdam due to Brexit

First Subject Dosed in Nevakar’s Phase III Trial of NVK-002 for Myopia in Children

ProQR Doses First Patient in Phase I/II Trial for Leber’s Congenital Amaurosis 10

Aston EyeTech Raises $6.6 Million in Series A Equity Round

Ellex Raises $17.7 Million in Private Placement

Genentech’s Lampalizumab Fails Second Phase III Study in Geographic Atrophy

Judge Declares Mistrial in Corruption Trial of Melgen, Menendez

Coming soon

2017 Dry Eye Products Report: A Global Market Analysis for 2016 to 2022